Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

0.30 

-0.03 -8.5%

as of Nov 29 '22

52 Week Range:

0.30 3.58


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 1.23
0.58
0.61
0.19
growth rate -52.9% 5.2% -68.9%
Earnings BIT -10.77
-10.65
-21.90
-30.54
-51.13
-39.33
-43.20
-62.88
-72.24
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -3.47
-3.26
-3.26
-3.26
-3.26
-3.26
growth rate 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -76.80
-51.27
-61.73
-49.59
-44.08
-41.65
-69.24
-64.83
-61.98
-59.90
-54.09
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -82.52
-54.63
-68.69
-58.00
-49.57
-47.84
-84.52
-80.66
-76.09
-206.25
-859.70
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -82.59
-55.26
-68.89
-58.64
-50.13
-48.30
-85.08
-81.24
-71.30
-77.65
-82.28
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 36.52
17.22
5.22
15.13
10.97
12.66
4.37
5.47
5.01
0.96
1.09
growth rate -52.9% -69.7% 189.9% -27.5% 15.4% -65.5% 25.2% -8.4% -80.8% 13.5%
Quick Ratio 36.39
17.11
5.19
13.96
10.58
12.44
4.10
5.26
4.66
0.81
0.87
growth rate -53.0% -69.7% 169.0% -24.2% 17.6% -67.0% 28.3% -11.4% -82.6% 7.4%
Leverage 1.07
1.06
1.20
1.15
1.11
1.18
1.27
1.22
1.23
13.00
20.42
growth rate -0.9% 13.2% -4.2% -3.5% 6.3% 7.6% -3.9% 0.8% 956.9% 57.1%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 0.43
1.06
0.22
0.49
2.26
1.40
1.64
29.29
32.52
growth rate 149.2% -79.3% 123.6% 359.8% -38.3% 17.2% 1,691.4% 11.1%
Acct.Payable 0.88
0.07
0.12
0.06
4.81
3.32
4.18
11.55
11.66
growth rate -92.5% 80.3% -49.6% 7,908.3% -30.8% 25.9% 176.1% 1.0%
Cur.Assets 12.60
26.02
60.51
67.82
51.68
56.79
53.21
70.50
89.15
growth rate 106.5% 132.6% 12.1% -23.8% 9.9% -6.3% 32.5% 26.5%
Total Assets 14.34
28.86
66.83
74.21
57.34
62.41
74.10
180.24
181.19
growth rate 101.2% 131.6% 11.1% -22.7% 8.8% 18.7% 143.2% 0.5%
Cash 11.85
5.89
21.52
53.79
16.46
29.01
29.02
29.30
29.47
growth rate -50.3% 265.2% 150.0% -69.4% 76.3% 0.1% 0.9% 0.6%
Inventory 0.65
0.77
1.88
6.53
14.81
growth rate 17.8% 144.7% 246.8% 126.9%
Cur.Liabilities 2.42
1.72
5.51
5.36
11.83
10.38
10.62
73.24
81.47
growth rate -28.8% 220.6% -2.9% 120.9% -12.3% 2.3% 589.9% 11.2%
Liabilities 2.42
3.85
6.75
11.51
12.28
11.23
14.10
166.38
172.31
growth rate 59.2% 75.6% 70.5% 6.7% -8.6% 25.6% 1,080.2% 3.6%
LT Debt 2.13
1.24
6.16
0.45
81.39
83.62
growth rate -41.8% 397.6% -92.7% 466.4% 2.7%
Equity 11.93
25.01
60.08
62.70
45.07
51.19
60.00
13.86
8.88
growth rate 109.7% 140.2% 4.4% -28.1% 13.6% 17.2% -76.9% -36.0%
Common Shares 5.00
5.00
6.00
9.00
11.00
13.00
18.00
0.77
0.96
1.05
1.50
growth rate 0.0% 20.0% 50.0% 22.2% 18.2% 38.5% -95.7% 25.4% 9.6% 41.8%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 0.01
0.07
0.01
0.09
0.15
0.02
0.17
0.41
0.12
growth rate 400.0% -80.0% 507.1% 71.8% -84.3% 630.4% 141.7% -71.7%
Cash From OA -8.44
-12.23
-17.83
-28.26
-44.77
-34.46
-40.75
-48.58
-65.05
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -1.68
-1.13
-2.39
-1.27
growth rate 0.0% 0.0% 0.0%
Sale Purchase of Stock 2.27
24.37
54.79
36.02
25.65
growth rate 973.1% 124.8% -34.3% -28.8%
FCF -5.00
-7.00
-9.00
-13.00
-19.00
-28.00
-46.00
-35.00
-41.00
-102.00
-65.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 0.01
7.01
0.00
0.10
4.01
8.36
6.29
64.36
85.76
growth rate 58,350.0% -100.0% 3,266.7% 3,867.3% 108.6% -24.8% 923.0% 33.3%
Op.Income -10.77
-10.65
-21.90
-30.54
-51.13
-39.33
-43.20
-62.88
-72.24
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -10.63
-10.71
-21.09
-29.37
-45.54
-38.82
-42.30
-76.17
-97.74
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -10.63
-10.71
-21.09
-29.37
-45.54
-38.82
-42.30
-76.17
-97.74
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -3.20
-2.00
-1.70
-1.30
-1.90
-2.40
-2.60
-1.70
-1.40
-2.10
-2.10
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 0.01
5.96
0.00
0.10
1.88
5.52
4.03
28.27
45.25
growth rate 49,600.0% -100.0% 3,266.7% 1,762.4% 193.6% -27.0% 601.1% 60.1%
R&D 8.10
12.70
17.77
25.24
32.97
24.86
17.42
16.49
29.50
growth rate 56.8% 39.9% 42.0% 30.6% -24.6% -29.9% -5.3% 78.9%

Quarterly Statements

Item Name Dec '20 Mar '21 Sep '21 Dec '21 Mar '22
Earnings BIT -19.71
-18.15
-17.40
-11.80
-13.24
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '20 Mar '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 29.29
23.31
30.04
32.52
25.93
growth rate -20.4% 28.9% 8.3% -20.3%
Acct.Payable 11.55
6.54
15.25
11.66
5.71
growth rate -43.4% 133.3% -23.5% -51.1%
Cur.Assets 70.50
112.66
83.12
89.15
72.58
growth rate 59.8% -26.2% 7.3% -18.6%
Total Assets 180.24
220.12
186.34
181.19
167.05
growth rate 22.1% -15.4% -2.8% -7.8%
Cash 29.30
75.97
23.25
29.47
28.85
growth rate 159.3% -69.4% 26.8% -2.1%
Inventory 6.53
9.27
13.12
14.81
14.27
growth rate 42.1% 41.5% 12.9% -3.6%
Cur.Liabilities 73.24
66.63
81.66
81.47
73.90
growth rate -9.0% 22.6% -0.2% -9.3%
Liabilities 166.38
167.08
174.79
172.31
172.29
growth rate 0.4% 4.6% -1.4% 0.0%
LT Debt 81.39
82.52
83.52
83.62
86.40
growth rate 1.4% 1.2% 0.1% 3.3%
Equity 13.86
53.04
11.55
8.88
-5.24
growth rate 282.6% -78.2% -23.2% -100.0%
Common Shares 1.05
1.31
1.32
1.50
1.51
growth rate 24.2% 0.5% 13.6% 0.7%
Cash Flow Statement Dec '20 Mar '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 0.05
0.09
0.02
0.00
0.01
growth rate 79.6% -76.1% -85.7% 333.3%
Cash From OA -12.71
-12.27
-19.03
-14.86
-4.16
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -12.75
-12.36
-19.05
-14.86
-4.17
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '20 Mar '21 Sep '21 Dec '21 Mar '22
Sales 21.46
20.58
21.61
22.07
18.24
growth rate -4.1% 5.0% 2.1% -17.4%
Op.Income -19.71
-18.15
-17.40
-11.80
-13.24
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -24.33
-22.86
-21.39
-24.37
-17.14
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -24.33
-22.86
-21.39
-24.37
-17.14
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 10.81
10.32
12.38
11.64
10.20
growth rate -4.5% 19.9% -6.0% -12.3%
R&D 6.19
7.48
5.82
5.87
3.06
growth rate 20.9% -22.3% 0.9% -47.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -3.26 -0.17 -0.88
EPS / Growth -1.73

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 0.01 0.01 0.67
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.